Pharmacokinetic/Pharmacodynamic Modelling of Antibacterials In Vitro and In Vivo Using Bacterial Growth and Kill Kinetics
- 1 January 2005
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 44 (2) , 201-210
- https://doi.org/10.2165/00003088-200544020-00005
Abstract
The minimum inhibitory concentration (MIC) is the in vitro reference value to describe the activity of an antibacterial against micro-organisms. It does not represent the dynamic effect of the antimicrobial at any point in time, but rather the total antimicrobial effect over the incubation period at a fixed concentration. To explore the concentration-effect relationship of antimicrobial concentrations against micro-organisms in relation to the MIC. Time-kill curves were generated for ceftazidime, meropenem and tobramycin against Pseudomonas aeruginosa. The Hill equation with variable slope was fit to the time-kill data, and mathematical models of growth and kill were explored with reference to the MIC. With declining concentrations, bacterial killing will decrease until a specific threshold concentration is reached. This concentration, at which bacteria are neither killed nor able to grow, is named the stationary concentration (SC) and is not equal to the MIC. Pharmacokinetic/pharmacodynamic simulations over a range of kill rates, growth rates and slope factors showed that for β-lactam antibacterials, the SC is close to the MIC value, which may explain why concentrations in vivo need to be above the MIC, while regrowth of bacteria occurs when concentrations decline below the MIC. For concentration-dependent antibacterials, such as aminoglycosides and quinolones, the SC is shown to be markedly different from the MIC and, in general, is much lower. The MIC is not a good pharmacodynamic parameter to characterise the concentration effect relationship of a given antimicrobial. For ‘concentration independent’ antimicrobials the SC is likely to be close to the MIC, but may be much lower for ‘concentration dependent’ antimicrobials, and may explain sub-MIC effects.Keywords
This publication has 17 references indexed in Scilit:
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugsInternational Journal of Antimicrobial Agents, 2002
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Dosage Regimens of AntibacterialsClinical Drug Investigation, 1996
- AntibactERial Activity of Four Cephalosporins in an ExpERimental Infection in Relation to In Vitro Effect and PharmacokineticsThe Journal of Infectious Diseases, 1990
- In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coliAntimicrobial Agents and Chemotherapy, 1989
- Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosaJournal of Pharmacokinetics and Biopharmaceutics, 1988
- Correction for bacterial loss in in vitro dilution modelsAntimicrobial Agents and Chemotherapy, 1987
- A Pharmacodynamic Model for the Activity of Antibiotics Against Microorganisms under Nonsaturable ConditionsJournal of Pharmaceutical Sciences, 1986
- Phenotypic Tolerance: The Search for β-Lactam Antibiotics That Kill Nongrowing BacteriaClinical Infectious Diseases, 1986
- Kinetics of antimicrobial activityThe Journal of Pediatrics, 1986